Showing 20 of 30 recruiting trials for “primary-myelofibrosis”
Momelotinib During and After HCT in Myelofibrosis
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
👨⚕️ Xiao Zhijian, Doctor, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)📍 2 sites📅 Started Feb 2026View details ↗
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
👨⚕️ Angela Flesichman, MD, PhD, Chao Family Comprehensive Cancer Center📍 1 site📅 Started Sep 2025View details ↗
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
👨⚕️ Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center📍 9 sites📅 Started Jan 2025View details ↗
RecruitingNCT06533813 ↗
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
👨⚕️ TIZIANO BARBUI, MD, FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS📍 36 sites📅 Started Oct 2024View details ↗
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
A Telehealth Advance Care Planning Intervention
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
👨⚕️ Zhijian Xiao, Doctor, Hematology Hospital, Chinese Academy of Medical Sciences📍 2 sites📅 Started May 2024View details ↗
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
RecruitingNCT06164561 ↗
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →